
Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-hmg-75iu
HMG (75IU)
High >98% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Human Menopausal Gonadotropin (HMG), also known as Menotropins, is a purified gonadotropin preparation derived from the urine of post-menopausal women. It contains both FSH (Follicle-Stimulating Hormone) and LH (Luteinising Hormone) activity in an approximately 1:1 ratio, providing comprehensive gonadotropin axis coverage that neither HCG nor gonadorelin alone can replicate.
In male reproductive research, FSH is the critical driver of spermatogenesis — it acts on Sertoli cells within the seminiferous tubules to support sperm maturation, while LH (or HCG as its surrogate) drives testosterone production in Leydig cells. In hypogonadotropic hypogonadism models, where both FSH and LH are deficient, HMG provides the complete gonadotropin signal required to stimulate both Sertoli and Leydig cell function simultaneously.
Research consistently demonstrates that HMG combined with HCG produces superior spermatogenesis induction outcomes compared to HCG alone, with improvements in sperm count, motility, and morphology. HMG is therefore a cornerstone compound in male infertility research where complete FSH/LH coverage is required.
Intended Research Use
- Spermatogenesis induction in hypogonadotropic hypogonadism models
- Sperm count, motility, and morphology improvement studies
- Combined FSH/LH gonadotropin research protocols
- Male fertility restoration research
- Endocrine axis restoration alongside HCG
- Gonadotropin replacement therapy models
menu_bookScientific Publications
International Journal of Reproductive BioMedicine (2014)
HMG 75 IU SC 3×/week improved sperm parameters in hypogonadotropic hypogonadism
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/24918081/
Reproductive Medicine and Biology (2018)
Combined hCG + HMG for male hypogonadotropic hypogonadism — FSH critical for spermatogenesis
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/29988283/
Translational Andrology and Urology (2018)
Indications for the use of hCG for the management of infertility in hypogonadal men
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/30159241/
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
HMG is designed to be used in combination with complementary gonadotropins for comprehensive male reproductive hormone research.

HCG 5000IU (5000IU vial)
arrow_forwardmyo-hcg-5000iu
Complete FSH/LH axis coverage — HCG provides LH-equivalent Leydig cell stimulation for testosterone, while HMG delivers the FSH component critical for Sertoli cell-driven spermatogenesis.

Gonadorelin Acetate (2mg vial)
arrow_forwardmyo-gonadorelin-acetate-2mg
Upstream pituitary stimulation layer — gonadorelin adds HPG axis signalling at the pituitary level, creating a three-level approach to gonadotropin axis restoration in hypogonadism research.

BPC-157 (5mg vial)
arrow_forwardmyo-bpc-157-5mg
Tissue repair adjunct — BPC-157's broad systemic healing properties complement reproductive organ function support during intensive gonadotropin stimulation protocols.
Cycling Note: HMG protocols require minimum 12 weeks for spermatogenic effect. Standard cycles: 12–16 weeks on, followed by reassessment. Monitor sperm parameters at weeks 12 and 16.